Recent clinical study reinforces Pacran™’s efficacy for women’s urinary health

A recent peer‑reviewed study published in The American Journal of Clinical Nutrition brings fresh confirmation of Pacran™’s efficacy in supporting urinary tract health.¹ Building on more than a decade of research, this latest clinical trial shows that Givaudan’s signature dried cranberry powder continues to deliver meaningful reductions in the incidence of urinary tract infections (UTIs) in women, strengthening Pacran™’s position as one of the most comprehensively studied cranberry ingredients worldwide.

Givaudan’s unique cranberry solution for urinary tract health

Cranberries contain specific phytochemicals known as proanthocyanidins (PACs), which were originally thought to be the primary compounds responsible for cranberry’s benefits. However, research conducted over the past 15 years suggests that the whole cranberry fruit plays an important role, rather than PACs alone.² Pacran™ capitalizes on these findings, capturing the full spectrum of cranberry actives. This recent study confirms that this whole‑fruit matrix, rather than a single compound, drives consistent benefits for urinary tract wellness.

The study: meaningful support for everyday comfort

Involving 150 healthy women with a history of recurrent UTIs, the randomized, double‑blind, placebo‑controlled trial evaluated 500 mg daily Pacran™ supplementation over six months.¹ Results revealed a statistically significant reduction in culture‑confirmed UTI incidence and extended the average time to first episode among participants taking Pacran™ compared to placebo.

Our latest results confirm Pacran™’s ability to offer consistent and clinically relevant benefits across independent studies. The robustness of this evidence sets a new benchmark for cranberry‑based solutions in urinary tract health.

The study¹ found that Pacran™ significantly (P ≤ 0.01):

• Reduced the risk of culture-confirmed UTIs by 52% compared with placebo
• Reduced the mean total number of UTIs per participant
• Reduced the incidence of urinary frequency and urgency symptoms
• Delayed the time to the first UTI episode compared with placebo

These results were both statistically and clinically significant, aligning with earlier findings^3,4 and further reinforcing the efficacy of Pacran™ in supporting urinary tract health.

Participants also saw a 58% reduction in the incidence of overall symptoms associated with UTI. These findings resonate with women seeking gentle, natural, science‑proven support for daily comfort. Reduced incidence and fewer symptoms mean fewer disruptions, translating to a tangible improvement in women’s quality of life.

Learn more about all of the benefits of Pacran™ here.

‍